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Purpose: We analyzed acurrent 78-month e~perience with externally supported (ringed) 
polytetrafluoroethylene (PTFE) axillobifemoral (AxBF) and axillounifemoral (AxUF) 
bypass grafts to address the controversy about whether the addition of a femorofemoral 
limb to an axillofemoral bypass graft improves the patency results. 
&I~thods: Between lanuary 1988 and June 1994, 36 AxBF and 22 AxUF externally 
supported PTFE ringed bypass grafts were performed at our institution. The age of the 
patients in the AxBF group was 67 +- 11 years and 69 -+ 11 years in the AxUF group. The 
male/female ratio was 22:13 (AxBF) and 8-9 (A.xUF). In 71% of cases (29/36 AxBF, 
12122 AxUF), the operations were performed for aortoiliac atherosclerotic o clusive 
disease in patients with significant medical risk factors or a "hostile" abdomen. The 
remaining 29% were patients requiring revascularization during treatment of an infected 
aortic graft. Bypass patency was assessed in the follow-up period by clinical evaluation, 
color-flow duplex imaging, or segmental limb pressure measurements. 
Results: There was no significant difference in the 30-day operative mortality rate for all 
AxBF bypasses (11%) and all AxUF bypasses (6%) (p = 0.89 by chi-squared testing). The 
primary and secondary patency rates for the whole group of bypasses were 80% and 89% 
at 3 years, respectively (SE < 0.1). Between the AxBF and AxUF groups, there were no 
significant differences in either primary patency (80% for each group) or secondary 
0 patency (91% in AxBFs vs 85 ~ in AxUFs) (SE < 0.1) at 2 years (Wilcoxon rank sum test). 
Conclusions: These data show no differences in the patency of externally supported PTFE 
AxBF and AxUF bypass grafts up to 2 years after implantation. (J VASC SURG 1995; 
21:801-9.) 
In 1961, Lewis! reported the use of the sub- 
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and HalIZ in the United States and in 1963 
3 bY Louw in SoUth Africa~ The further addition 
of a femorOfemoral crossover fimb as initially 
Suggested by Sauvage and Wood 4 offered a simple 
o~tion ifor reVasc~arization of both lower ex- 
~emitiesi ~ l l6~i femora l  (AxUF) or axiUobi- 
femoral (~F)  bypass procedures have been 
Used mainly for fimb Salvage in patients at high risk 
wi th  aortoiliac occlusive disease or similar patients 
With a::~h0stiie ', abdomen or for revascularization 
o f  patients requiring removal of  a functioning 
infected aortiC: graft.4! ~ Controversy remains re- 
garNng whether the addition of  a femorofemoral 
limb will improve  late patency results. 7,913 To 
address this issue, we evaluated a current 78-month 
experience with externally supported polytetraflu- 
oroethylene (PTFE) AxBF and AxUF bypass grafts. 
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Table I. Patient demographics and indications for the axillofemoral grafts 
AxBF bypass AxUF bypass p Values 
No. of procedures 36 22 
No. of patients 35 17 
Age (yr) 67 + 11 69 -+ 11 p = 0.54* 
Male/female 22 : 13 8 : 9 p = 0.43t 
Emergency procedures 36% 41% p = 0.931t 
Elective procedures 64% 59% p = 0.931t 
Atherosclerotic disease 29 (80%) 12 (55%) p = 0.07t 
Acute ischemia 12 (33%) 9 (41%) 
Gangrene 1 (3%) 0 (0%) 
Nonhealing ulcer 3 (8%) 0 (0%) 
Rest pain 13 (36%) 1 (5%) 
Infection 7 (20%) 10 (45%) p = 0.07t 
Aortic graft infection 6 (17%) 10 (45%) 
Aortoduodenal fistula 1 (3%) 0 (0%) 
*By t testing. 
tBy chi-squared testing. 
Table II. Associated medical risk factors 
Condition AxBF AxUF p Value* 
Hypertension 51% 65% p = 0.544 
Diabetes meUitus 37% 22% p = 0.505 
Coronary artery disease 57% 59% p = 0.854 
COPD 34% 24% p = 0.640 
Chronic kidney failure 9% 12% p = 0.893 
Previous aortic surgery 17% 29% p = 0.513 
Age >75 years 23% 35% p = 0.528 
COPD, Chronic obstructive pulmonary disease. 
*By chi-squared testing. 
PATIENTS AND METHODS 
We evaluated the results of all the externally 
supported (ringed) PTFE AxBF and AxUF bypasses 
done between January 1988 and June 1994 at the 
University of Iowa Hospitals & Clinics. The medical 
records of all of these patients were reviewed. 
Information gathered from the medical records 
included patient demographics, associated medical 
illnesses, indication for surgery, and prior and 
subsequent vascular procedures. Relevant preopera- 
tive diagnostic study results uch as segmental limb 
pressures, duplex study results, and arteriograms 
were reviewed. The patients' records were also 
reviewed for the type and diameter of graft, bypass 
configuration, outflow artery, runoff status, and 
perioperative and late complications. Information 
regarding the postoperative use of aspirin or warfarin 
(Coumadin) was also gathered from the medical 
records. Patients were evaluated in the vascular 
surgery clinic at i month after the procedure, then at 
6-month intervals for the first year, and yearly 
thereafter. A similar protocol was followed if a 
patient underwent a bypass revision or new bypass 
procedure. In addition to a clinical evaluation, 
segmental limb pressure measurements or color-flow 
duplex imaging of the bypass graft was done during 
each clinic visit. 
Brachial systolic blood pressures in both arms 
were measured before operation. If both pressures 
were normal, the inflow site chosen was usually on 
the side of the most ischemic lower limb. If there was 
evidence of unilateral inflow axillary artery disease the 
normal contralateral xillary artery was used as the 
inflow artery. Arteriographic studies were not rou- 
tinely used to evaluate the inflow, but duplex 
scanning was occasionally used for this purpose. Each 
axillary anastomosis was to the anterior aspect of the 
first part of the axillary artery. The vertical limb of the 
bypass was tunneled along the posterior axillary line 
and a counterincision was avoided, if possible. The 
femorofemoral component of the AxBF graft origi- 
nated from the lower end of the vertical limb of the 
bypass and was tunneled subcutaneously to the native 
artery in the contralateral groin by use of an inverted 
C configuration in 28 bypasses and in a lazy g 
configuration i eight bypasses. 
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The CUlnulative primary and secondary parency 
rates for the bypass grafts were calculated by life-table 
analysis as per the recommendations of the Society 
for Vascular Surgery/International Society for Car- 
diovascular Surgery Ad Hoc Committee on Sug- 
gested Standards in Reporting of Lower Extremity 
Bypasses. 14 Because a patient with bilateral AxUF 
bypasses has two separate bypass grafts, the patency 
results were calculated and analyzed per graft and not 
per patient o compare the outcome of all AxUF and 
AxBF bypasses. In the case of AxBF bypasses, a graft 
was considered patent only when both the axil- 
lofemoral and the femorofemor{tl components were 
patent. Patient demographics between the AxBF and 
AxUF bypass groups were compared for any statis- 
tical differences by  r testing. Both the primary and 
secondary patency rates between AxBF and AxUF 
bypasses were analyzed for statistical differences by 
the Wilcoxon rank stun test. Other variables uch as 
indications for surgery and theass0ciated medical risk 
factors between AXBF and AxUF bypass groups were 
compared by use of chi-square testing. Ap value less 
than 0.05 was considered significant. 
RESULTS 
Thirty-six AxBF and 22 AxUF externally sup- 
ported (ringed) PTFE bypass grafts were done at the 
University of Iowa Hospitals & Clinics from January 
1988 to June i994. Patient demographics and the 
indications for the bypasses are depicted in Table I. 
Five patients (three inthe AxBF group and two in the 
AxUF group) t!ad a prior AxBF that had failed. The 
secondary axillofemoral bypass grafts originated 
from the opposite axiUary artery. The medical risk 
factors for both the groups are compared in Table II. 
Twenty-two patients required emergency revascular- 
ization. 
In the AxBF group, both lower extremity super- 
ficial femoral arteries were patent in 19 cases (53%), 
only one superficial femoral artery was patent in 10 
cases (28%), and both were occluded in four cases 
(11%). The status of the superficial femoral arteries 
was not knownl before three emergency procedures 
(8%) because arteriography was not performed. In 
the AxUF bypass group, the ipsilateral superficial 
femoral artery was patent in 14 cases (64%), oc- 
cluded in four cases (18%), and of unknown status in 
four emergency cases (18%). In both the AxBF and 
AxUF bypass groups, all limbs with a patent 
femoropopliteal/tibial bypass were listed as having a 
patent superficial femoral artery. 
All the bypasses inthis series were performed with 
use of PTFE grafts with externally supported rings. 
The graft diameter in the vertical imb of 33 AxBF 
bypasses was 8 mm and in the other three was 6 mm. 
An 8 mm-diameter graft was used in 16 AxUF 
bypasses and a 6 mm diameter graft in the remaining 
six. 
There were four deaths in the AxBF group and 
one death in the AxUF group during the 30-day 
postoperative p riod, resulting in an overall (both 
elective and emergency procedures) operative mor- 
tality rate of 11% for the/LxBF group and 6% for the 
AxUF group (p = 0.89by chi-squared testing). In 
the AxBF group three deaths occurred after emer- 
gency revascularization procedures, and one occurred 
after an elective procedure. The causes of death in the 
three patients who died after emergency AxBF bypass 
grafting Were septic shock (n - 1) and multisystem 
organ failure (n = 2). The death after an elective 
AxBF bypass was due to a postoperative myocardial 
infarction. One patient in the AxUF group died 1 day 
after emergency revascularization as a result of a 
myocardial infarction. Thus, for elective revascular- 
ization procedures, the 30-day operative mortality 
rate for AxBF and AxUF bypass grafts was 4% and 
0%, respectively. 
During the postoperanve period one patient in 
the AxBF group required a femoropopliteal bypass 
on day l0 for distal ischemia of the lower extremity 
despite the patent AxBF bypass. Two patients with 
AxBF bypasses underwent evacuation of a hematoma 
in the axillary region on postoperative day 2 and 10, 
respectively. The latter patmnt was receiving Couma- 
din. One patient with an AxUF bypass underwent 
exploration and evacuation of an axillary hematoma 
on postoperative day 2. This patient was not receiv- 
ing anncoagulation. 
One patient with rest pain of the left leg under- 
went an AxBF bypass and 13 months later, despite a
patent bypass, underwent a right below-knee ampu- 
tation for a chronic infected venous tasis ulcer with 
osteomyelitis. Another patient who had a throm- 
bosed AxUF bypass underwent an above-knee ampu- 
tation on postoperative day 1 because of progressive 
advanced ischemia. There was no significant differ- 
ence in the amputation rates between the AxBF and 
AxUF bypass groups (p = 0.69 by chi-squared 
testing). 
Disruption at an axillary and femoral anastomosis 
(one each) was seen in two patients with an AxBF 
graft. The patient with a proximal anastomotic 
disruption had development of this 2 weeks after 
operation, possibly as a result of forced exertion of 
the upper limb. The patient with a femoral anasto- 
motic disruption had development of this 3 weeks 
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after the surgical procedure. In this case the suture 
line was intact, but the PTFE graft at the distal 
anastomosis was torn. Both these disruptions were 
revised with an interposition PTFE graft to bridge 
the defect. The former patient underwent a successful 
thrombectomy for graft thrombosis 6 months later 
that subsequently occluded, requiring a new AxUF 
bypass with inflow from the contralateral xillary 
artery. The latter patient with the femoral anasto- 
motic disruption has a patent graft at follow-up 12 
months later. 
Five of the AxBF bypass grafts thrombosed 
during the follow-up period (Table III). They were 
all 8 mm-diameter grafts. Three thromboses oc- 
curred within 24 hours (perioperative thrombosis), 
and the other two were late thromboses at18 and 31 
months after graft implantation. All the thromboses 
in the AxBF group involved the vertical limb of the 
bypass, as well as the femorofemoral limb except in 
one patient who had thrombosis of the femorofemo- 
ral component alone detected by duplex examination 
1 month after the surgery. Because the patient did not 
have any symptoms, he did not undergo further 
intervention for the thrombosed crossover limb. 
One patient with an AxUF bypass graft had 
development of a perioperative graft thrombosis 
(< 24 hours) and another patient had development 
of a graft thrombosis at 3 weeks. Two other patients 
had development of late graft thromboses (4 and 9 
months later). All four graft thromboses in the AxUF 
bypass group occurred in patients with 8 mm 
diameter grafts, and none in 6 mm diameter grafts. 
There was no statistically significant difference 
between the thrombosis rate in either the AxBF and 
AxUF groups with regard to whether the superficial 
femoral arteries were patent or occluded (/9 = 0.38 
and 0.80 by chi-squared testing). Similarly, with 
both groups combined, there was no significant 
difference between the rate of thrombosis whether 
the superficial femoral artery was patent or occluded 
(p = 0.31 by chi-squared testing). 
Postoperative anticoagulation therapy alone with 
Coumadin was instituted, in 11% and 36% of the 
cases in the AxBF and AxUF groups, respectively. 
Similarly, 19% of the cases in the AxBF group and 
5% of the cases in the AxUF group were on aspirin 
therapy alone after the bypass procedure. In the 
AxBF group 36% of the cases were on both 
Coumadin and aspirin therapy compared with 18% 
of the cases in the AxUF group. Thirty-three percent 
of AxBF and 41% of AxUF cases did not receive 
either Coumadin or aspirin (p = 0.76 by chi-squared 
testing). The effect of C0umadin or aspirin therapy 
on the patency of the AxBF and AxUF bypasses i
depicted in Table IV. Because there were only small 
numbers of grafts in each of these groups, a 
comparison of the patency of the AxBF and AxUF 
bypass in each category was not done. The patency of 
the grafts in both the AxBF and AxUF group with 
regard to the status of the superficial femoral artery 
and the Coumadin therapy is depicted in Table V. 
For all the bypasses combined together the 
cumulative primary and secondary patency rate by 
life-table analysis was 80% and 89% at 3 years 
(SE < 0.1) (Fig. 1). The primary and secondary 
patency rates of AxBF and AxUF bypasses are 
depicted in Figs. 2 and 3. When the two groups were 
compared, it was found that there was no significant 
difference in the primary patency rate at 2 years (80% 
for each group, SE < 0.1) nor any significant differ- 
ence between secondary patency rates in the two 
groups (91% for AxBF and 85% for AxUF) at 2 years 
(SE < 0.1). 
DISCUSSION 
Controversy still exists regarding whether the 
addition of a femorofemoral limb improves the 
patency of an axillofemoral bypass graft. In contra- 
distinction to the positive reports ofLoGerfo et al.,15 
Rutherford et al., 1~ Kalman et al., 16 Burrell et al., 7 
and Hepp et al.17 that favor the use of an AxBF over 
an AxUF graft, Ascer et al.13 demonstrated no 
difference in patency rates between such grafts. In the 
report by Ascer et al. 13 nonringed AxBF PTFE bypass 
grafts had a 5-year cumulative primary rate and 
secondary patency rate of 50% and 77%, which were 
not significantly different from the patency rates of 
AxUF bypasses (44% and 71%). The 2-year primary 
patency rate of AxBF bypasses in our series was 80% 
and is comparable to the 2-year data for similar 
bypasses of 70% to 90% reported by LoGerfo et al.,i5 
Rutherford et al.]4 Kalman et al.,16 Burrell et al.,7 
and Hepp et al.17 However, the 2-year primary 
patency rate of AxUF bypasses in our study was 
markedly superior to the 2 year results of earlier 
reports (80% vs 30% to 60%). LoGerfo et al. 15 
suggested that the improved patency of their AxBF 
bypass grafts was due to increased blood flow 
through the vertical limb of the axillofemoral bypass 
proximal to the take off of the crossover femoral limb. 
Several reports from other centers had confirmed the 
findings of LoGerfo et al. that AxBF grafts had 
patency rates of 71% to 78% at 3 years compared 
with 37% to 58% for AxUF bypasses. 7,i~ Ray et 
al.,t2 however, reported contradictory findings in 
their series of USGI Sauvage filamentous velour 
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Table I I I .  AxBF and AxUF bypass graft thrombosis: cause and outcome 
No. Occurrence Cause Management Current status 
AxBF graft thrombosis 
1 < 24 hours 
2 < 24 hours 
3 < 24 hours 
4 18 months 
5 31 months 
AxUF graft thrombosis 
1 < 24 hours 
Platelet plus at distal 
anastomosis 
Thrombosis of pro- 
funda femoris 
Hypotension + CVA 
Subtherapeutic antico- 
agulation 
CVA + seizures 
Recurrent thrombosis 
of femoral artery 
2 3 weeks Recurrent thrombosis 
of femoral artery 
3 4 months Unknown 
4 9 months Thrombosis of fem-pop 
bypass 
Thrombectomy, aspirin, 
Coumadin 
Thrombectomy, jump 
graft to distal pro- 
funda femoris, Cou- 
madin 
No intervention 
Thrombectomy, Cou- 
madin 
No intervention 
Patent at 11 months 
Patent at 21 months 
Died because of CVA 2 
months later 
Patent at 36 months 
Died because of CVA 4 
days later 
Above-knee amputation Alive 
for continued 
ischemia 
New AxUF (unsuccess- Patent 
ful thrombectomy) 
Successful thrombec- Patent 
tomy at 4, 6, and 17 
mos~ 
Ilioprofunda bypass Patent at 21 months 
CVA, Cerebrovascular accident; fern-pop, femoropopliteal. 
Table IV. Effect of aspirin or Coumadin 
on patency of grafts 
AxBF AxUF 
(patent (patent 
grafts/total grafts/total 
number) number) 
Aspirin therapy 5/7 1/1 
Coumadin therapy 3/4 6/8 
Aspirin + Coumadin 12/13 4/4 
therapy 
None 11/12 7/9 
Dacron grafts (United States Catheter and Instru- 
ment, C. R. Bard, Inc., Billerica, Mass.). Their 
secondary patency rate at 9 years for AxBF bypass 
grafts was 77%, not significantly different from 67% 
for AxUF bypass grafts. 12 Several other authors more 
recently have reported no significant difference in 
patency rates between AxBF and AxUF bypass 
grafts, ls1921 In the small sample size of our study, 
there was no statistically significant difference be- 
tween the patency rates between AxBF and AxUF 
grafts. One may speculate, however, whether there 
would be a significant difference if there was a larger 
sample size to compare the patency of AxBF and 
AxUF bypasses. Although it was not statistically 
significant, a greater percentage ofthe AxUF grafts in 
our series were performed for aortic graft infection. 
However, the original indication for most previous 
Table V. Effect of SFA status and 
Coumadin therapy on patency of grafts 
AxBF AxUF 
(patent (patent 
gratis/total grafts/total 
number) number) 
Patent SFA on 6/7 7/8 
Coumadin 
Patent SFA off 10/11 2/3 
Coumadin 
Occluded SFA on 8/10 5/5 
Coumadin 
Occluded SFA off 8~ 9 4 '6 
Coumadin 
SFA, Superficial femoral artery. 
aortic grafts was atherosclerotic occlusive disease. 
Additionally the runoffstatus ofthe AxBF and AxUF 
groups in our series were similar. In our study, the 
indication for the bypass had no bearing on the 
patency results. 
In 1979 Campbell et al. 22 first reported the use of 
PTFE for extraanatomic reconstructive procedures. 
A major advantage of PTFE is that a thrombectomy 
can be performed more easily than with other grafts, 
especially crimped Dacron. Most early reports of 
axillofemoral bypass grafting had a 35% to 50% 
incidence of thrombosis.6,7 Hence, the ease of throm- 
bectomy of PTFE grafts in this location was per- 
ceived as an advantage. 7'232s In 1978, Dacron grafts 
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with externally supported rings became available, and 
two series reported a markedly improved patency rate 
with these conduits for AxBF and AxUF by- 
passes. 19,26 In 1980, Alexander et at. 2a reported a 79% 
primary patency rate at 21 months with nonringed 
PTFE grafts for 29 axillofemoral bypasses. A similar 
patency rate at 2 years has been reported in a 
nonringed PTFE series consisting of 34 AxBF and 23 
AxUF bypasses. 27The use of externally supported 
PTFE grafts, which became available in 1981, have 
also been reported to be responsible for the improved 
patency rates of both AxUF and AxBF bypasses 
compared with historic controls. 2s'29 The improved 
results reported with the use of externally supported 
grafts could be due to the fact that these grafts are 
resistant to external graft compression. On the 
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contrary, Jarowenko et al. 3~ failed to demonstrate any 
changes in the pulse volume recording and segmental 
Doppler pressure measurements in the calf and ankle 
by attempted graft compression of nonringed axil- 
lofemoral bypasses, by having the patient lie on their 
graft. The low incidence of graft thrombosis noted in 
our series and those of others using externally 
supported ringed grafts suggests that an externally 
supported conduit is an important factor that con- 
tributes to improved patency rates. 
LoGerfo et al.iS and Rutherford et al. to suggested 
that the patency of an AxUF or AxBF bypasses i
influenced by the patency of the superficial femoral 
arteries. However, reports from other authors have 
failed to confirm this finding. 13,19,29 In our current 
study, the patency of the superficial femoral arteries 
did not appear to influence patency of the extraana- 
tomic bypasses in either group. A severely diseased 
yet patent superficial femoral artery could be present 
in some patients, thus explaining why patency alone 
is not adequate to assess runoff. 
We conclude that a patient at high risk with 
unilateral limb ischemia is well served with an AxUF 
bypass graft when a simple, local endovascular, 
iliofemoral or femorofemoral bypass option is not 
available. The addition of a femorofemoral compo- 
nent to an AxUF bypass graft merely to lower the 
outflow resistance appears unnecessary unless the 
opposite limb is also ischemic and symptomatic. An 
AxBF bypass remains a suitable option when revas- 
cularization of both the lower extremities i  required 
in a patient at high risk with atherosclerotic o clusive 
disease or after removal of an infected aortic graft. 
The use of externally supported ringed conduits may 
be a factor that is important in maintaining long-term 
patency of AxUF and ExBF bypass grafts. 
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DISCUSSION 
Dr. Terry A. King (Cleveland, Ohio). The authors 
addressed a question that many of us face on a regular basis, 
namely whether the cross-femoral portion of the bypass is 
necessary for long-term patency when considering axil- 
lofemoral bypass for lower extremity revascularization. 
They provide a large, recent series of patients and bypasses 
with current surgical techniques, graft material, and 
perioperative care. They also had the fortitude to perform 
a significant number of AxUF bypasses when the general 
consensus i that the cross-femoral limb is important o 
long-term patency. 
There are several considerations in the use of axil- 
lofemoral bypass, including patient selection, distal runoff, 
and the use of outflow procedures, as well as graft selection 
and the use of anticoagulation. With respect to the patient 
selection, I presume the large number of patients with 
infected aortic graft placement reflects the tertiary referral 
nature of your practice. 
Regarding distal runoff and the importance of outflow, 
several authors that you quote show that the superficial 
femoral artery patency isimportant to long-term patency of 
the axillofemoral bypass. Taylor and his colleagues 29from 
Portland show the generous use of concomitant outflow 
procedures to improve patency rates of their axillofemoral 
grafts. Certainly the procedure is technically easier in the 
face of a patent superficial femoral artery. 
Regarding graft selection and type, it seems to be 
inferential, but the use of externally supported PTFE 
appears to have contributed to long-term patency of this 
axillofemoral procedure. 
You show no clear significance that outflow is impor- 
tant regarding superficial femoral artery patency, or for that 
matter, the importance of the cross-femoral llmb. What 
component does outflow resistance have with respect o 
patency? 
My second question has to do with your indications 
and the use of anticoagulation. It is not extremely clear 
which patient receives Coumadin versus aspirin. 
Do your data support he preferential use of externally 
supported PTFE grafts without any further andomization 
or studies comparing it with other materials? 
Dr. Chittur R. Mohan. Outflow resistance probably 
JOURNAL OF VASCULAR SURGERY 
Volume 21, Number 5 Alohan et al. 809 
plays an important roie in the patency; however, it is not 
necessary to add a cross-over femoral imb to decrease the 
outflow resistance. Patency is dependent on the outflow 
resistance on the side of the ischemic limb. Other people 
have correlated superficial femoral artery (SFA) patency 
with results. In  thi s study we did not find any significant 
difference~ A patent, SFA ma. y still be diseased; plus outflow 
resistance may be:higher on the same side because of disease 
other than the SFA below the knee level: So certainly 
outflow probably plays an important :role, but pateney of 
SFA itself did not correlate in Our Study, 
With regard to your question regarding anticoagula- 
tion, most of our  patients are on aspirin or coumadin. 
therapy and probably this contributed: to the good results 
that we had in our study.. We certainly believe in starting 
everybody on aspirin therapy unless there i sa  contraindi- 
cation. As far as~.anticoagulation wi th  Coumadin is 
concerned, we believe that patients with poor outflow 
should be on Coumadin therapy. If  the patient has any 
history suggestive of a hypercoagulable state in the past, we 
definitely put them on Coumadin therapy. If  the patient has 
a single episode of thrombosis, even if we can't find a cause 
for that, we will put them on Coumadin therapy m the 
follow-up period. 
With regard to the use of externally supported PTFE 
grafts, there has been no difference between externally 
supported PTFE versus externally supported Dacron. We 
didn't compare them in our study because we don't have 
much data on externally supported Dacron. We preferen- 
tially use externally supported PZFE because the patency 
results with externally supported Dacron and PTFE are 
compatible, plus PTFE also has the added advantage of ease 
of ~rombectomy in case:an occlusion should occur. So, 
because of these two factors, we believe m using an 
externally supported PTFE graft; The data on axillofemoral 
bypass have certainly improved with the introduction of 
externally supported grafts. As .far as the patency is 
concerned, there is no difference between Dacron or PTFE 
as long as they are externally supported: however, throm- 
bectomy is easier with PTFEI 
